Related references
Note: Only part of the references are listed.DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase-2 trial of low-dose pomalidomide in myelofibrosis
K. H. Begna et al.
LEUKEMIA (2011)
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
D. Caramazza et al.
LEUKEMIA (2011)
Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy
Michelle A. Neben-Wittich et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
Alejandra Martinez-Trillos et al.
ANNALS OF HEMATOLOGY (2010)
Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Fabio P. S. Santos et al.
BLOOD (2010)
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia
Cynthia L. Fisher et al.
BLOOD (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
Ruben A. Mesa et al.
BLOOD (2010)
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
Franz X. Schaub et al.
BLOOD (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Guellue Goerguen et al.
BLOOD (2010)
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
Haefaa Alchalby et al.
BLOOD (2010)
The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study
W. A. Stewart et al.
BONE MARROW TRANSPLANTATION (2010)
JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation
Seido Oku et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms
Sool Yeon Cho et al.
CANCER RESEARCH (2010)
ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1
Sang-Wang Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sachie Marubayashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Lnk constrains myeloproliferative diseases in mice
Alexey Bersenev et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
A. Tefferi et al.
LEUKEMIA (2010)
Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin
G. Li et al.
LEUKEMIA (2010)
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
A. Tefferi et al.
LEUKEMIA (2010)
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
A. Pardanani et al.
LEUKEMIA (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
R. Jaeger et al.
LEUKEMIA (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
LNK Mutations in JAK2 Mutation-Negative Erythrocytosis.
Terra L. Lasho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category
Ulrike Bacher et al.
ANNALS OF HEMATOLOGY (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm
Jonathan R. Lambert et al.
BLOOD (2009)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli et al.
BLOOD (2009)
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kroeger et al.
BLOOD (2009)
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
Yongchao Wang et al.
BLOOD (2009)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis H. Grand et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones
Philip A. Beer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level
Jocelin Huang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function
Daniel Trageser et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
Sigal Gery et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Mutations of ASXL1 gene in myeloproliferative neoplasms
N. Carbuccia et al.
LEUKEMIA (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms
Masashi Sanada et al.
NATURE (2009)
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Mamta Tahiliani et al.
SCIENCE (2009)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Francesca Patriarca et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
A. Quintas-Cardama et al.
LEUKEMIA (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani et al.
BLOOD (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi et al.
BLOOD (2007)
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis:: cytogenetic and JAK2V617F molecular remissions
A. Tefferi et al.
LEUKEMIA (2007)
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Ayalew Tefferi et al.
BLOOD (2006)
Palliative goals, patient selection, and perioperative platelet management - Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
Ruben A. Mesa et al.
CANCER (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Microcytosis in agnogenic myeloid metaplasia: Prevalence and clinical correlates
A Tefferi et al.
LEUKEMIA RESEARCH (2006)
Thalidomide therapy for myelofibrosis with myeloid metaplasia
DA Thomas et al.
CANCER (2006)
Pathogenesis of myelofibrosis with myeloid metaplasia
A Tefferi
JOURNAL OF CLINICAL ONCOLOGY (2005)
Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia
M Massa et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes
DP Steensma et al.
BLOOD (2005)
Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia:: long-term results in 30 patients
F Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia
A Orazi et al.
MODERN PATHOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia
LN Faoro et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial
M Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia:: results in 20 patients and review of the literature
F Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Nonhepatosplenic extramedullary hematopoiesis: Associated diseases, pathology, clinical course, and treatment
CA Koch et al.
MAYO CLINIC PROCEEDINGS (2003)
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
RA Mesa et al.
BLOOD (2003)
Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia
DP Steensma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Myelodysplasia with fibrosis: a distinct entity?
DP Steensma et al.
LEUKEMIA RESEARCH (2001)
Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia
A Tefferi et al.
BLOOD (2001)
Share Paper
